Author(s):
Dr. Pragati Baghel, Dr. A. Purushothaman, Dr. Anurag rawat, S.Gopi Krishnan, Mr. Yogesh Matta
Email(s):
pragatipharma20@gmail.com , purushothamanbiochem@gmail.com , anuragrwt@gmail.com , yogesh.matta@mygyanvihar.com
Address:
Professor
Faculty of Pharmacy, Bharti Viswavidyalaya
Principal and Professor of Biochemistry
PERI College of Arts and Science (Affiliated to University of Madras)
PERI Knowledge Park, Mannivakkam, Chennai-600 048, Tamil Nadu, India
Professor
Himalayan Institute of Medical Science, 248140
Associate Professor
Arulmigu Kalasalingam College of Pharmacy,
Anand Nagar, Krishnakoil, Tamilnadu, 626 126
Associate Professor
Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur
Pin : 302017
Published In:
Book, TARGETING DIABETES THROUGH PRECISION MEDICINE AND DRUG DELIVERY TECHNOLOGIES
Year of Publication:
December, 2025
Online since:
January 24, 2026
DOI:
Not Available
ABSTRACT:
Modern diabetes management has shifted from reactive glucose monitoring to a proactive, molecular-driven paradigm. While traditional markers like $HbA_{1c}$ provide a glycemic history, they lack the granularity to predict individual complications or drug responses. In the era of precision medicine, molecular diagnostics—including Next-Generation Sequencing (NGS) and Polygenic Risk Scores (PRS)—allow for the precise identification of monogenic diabetes and the stratification of Type 2 sub-phenotypes. Furthermore, novel biomarkers such as circulating microRNAs ($miR-126$, $miR-21$) and metabolomic signatures (e.g., branched-chain amino acids) serve as early warning systems for nephropathy and cardiovascular risk. By integrating these high-sensitivity molecular tools with AI-driven analytics, clinicians can now move toward "hyper-personalized" therapy, significantly reducing the "trial-and-error" phase of treatment and improving long-term patient outcomes through early, targeted intervention.
Cite this article:
.
References not available.